|
May 6
|
Bulletin from the Annual General Meeting of Vicore Pharma Holding AB (publ)
|
|
May 6
|
Interim Report January – March 2025
|
|
May 2
|
Vicore to Present at the Nordea Equities Healthcare Seminar
|
|
May 20
|
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
|
|
Feb 9
|
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan
|